SCHEMBL16447253

SCHEMBL16447253

O=C(O)CCC[C@H](NC(=O)c1ccc(F)cc1)C(=O)N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 14/20 0.53
FOLH1 Q04609 4/20 0.47
PIN1 Q13526 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447254 1.00 KDM1A (0.53) KDM1AFOLH1PIN1
SCHEMBL16455163 0.91 KDM1A (0.53) KDM1APIN1
SCHEMBL16447281 0.88 KDM1A (0.51) KDM1A
SCHEMBL20924673 0.88 KDM1A (0.51) KDM1A
SCHEMBL16447279 0.88 KDM1A (0.51) KDM1A
SCHEMBL16446910 0.86 KDM1A (0.61) KDM1A
SCHEMBL18043482 0.86 KDM1A (0.61) KDM1A
SCHEMBL16455182 0.86 KDM1A (0.53) KDM1A
SCHEMBL28065333 0.84 KDM1A (0.49) KDM1APIN1
SCHEMBL18043479 0.83 PHGDH (0.50) KDM1APIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 US disclosed
US-20210147373-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-05-20 US disclosed
US-20210147373-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-05-20 US disclosed
US-10882835-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2021-01-05 US disclosed
US-10882835-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2021-01-05 US disclosed
US-20200095214-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2020-03-26 US disclosed
US-10370346-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2019-08-06 US disclosed
US-10370346-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2019-08-06 US disclosed
US-20170334873-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2017-11-23 US disclosed
US-9790195-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2017-10-17 US disclosed
US-9790195-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2017-10-17 US disclosed
US-9790195-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2017-10-17 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2016-09-08 US disclosed
EP-3030323-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2016-06-15 EP disclosed
WO-2015021128-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC. (US) 2015-02-12 WO disclosed
WO-2015021128-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC. (US) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334873-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885
US-10882835-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885
US-20160257662-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3931/4885PIN1 4639/4885
US-10370346-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885
US-20200095214-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885
US-20210147373-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885
US-11655226-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885FOLH1 3753/4885PIN1 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.